Associated Genetic Biomarkers
Associated Diseases
Associated Pathways

Overview

Location [1]
1p13.2
Pathway
MAP kinase signaling
Protein [2]
GTPase NRas
Synonyms [1]
NCMS, CMNS, NS6, N-ras, NRAS1, ALPS4

NRAS (neuroblastoma RAS viral (v-ras) oncogene homolog) encodes for the GTPase NRas protein, one of three human RAS proteins. RAS proteins are small GTPases that are central mediators downstream of growth factor receptor signaling and therefore critical for cell proliferation, survival, and differentiation. NRAS is implicated in the pathogenesis of several cancers (for review see PMID: 17384584).

NRAS is altered in 2.57% of all cancers with cutaneous melanoma, melanoma, colon adenocarcinoma, acute myeloid leukemia, and lung adenocarcinoma having the greatest prevalence of alterations [3].

NRAS GENIE Cases - Top Diseases

The most common alterations in NRAS are NRAS Mutation (3.80%), NRAS Mutation (germline) (3.80%), NRAS Mutation (somatic) (3.80%), NRAS Exon 3 Mutation (2.57%), and NRAS Exon 3 Missense (2.55%) [3].

NRAS GENIE Cases - Top Alterations

Biomarker-Directed Therapies

Significance of NRAS in Diseases

Melanoma +

Malignant Solid Tumor +

Colorectal Carcinoma +

Non-Small Cell Lung Carcinoma +

Acute Myeloid Leukemia +

Myelodysplastic Syndromes +

Chronic Myelomonocytic Leukemia +

Non-Hodgkin Lymphoma +

Multiple Myeloma +

Acute Lymphoblastic Leukemia +

Colorectal Adenocarcinoma +

Pancreatic Carcinoma +

Glioma +

Cancer +

Ovarian Carcinoma +

Neurofibromatosis Type 1 +

Pancreatic Ductal Adenocarcinoma +

Poorly Differentiated Thyroid Gland Carcinoma +

Squamous Cell Lung Carcinoma +

Breast Carcinoma +

Histiocytic And Dendritic Cell Neoplasm +

Neuroblastoma +

Small Cell Lung Carcinoma +

Thyroid Gland Undifferentiated (Anaplastic) Carcinoma +

Thyroid Gland Follicular Carcinoma +

Thyroid Gland Adenocarcinoma +

Thyroid Gland Carcinoma +

Low Grade Ovarian Serous Adenocarcinoma +

Thyroid Gland Papillary Carcinoma +

Rhabdomyosarcoma +

Rectal Carcinoma +

Colon Carcinoma +

Lymphoma +

Endometrial Carcinoma +

Soft Tissue Sarcoma +

Bladder Carcinoma +

Sarcoma +

Glioblastoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Anaplastic Astrocytoma +

Chronic Myeloid Leukemia +

Diffuse Large B-Cell Lymphoma +

Double-Hit Lymphoma +

Gastric Adenocarcinoma +

Head And Neck Carcinoma +

Head And Neck Squamous Cell Carcinoma +

Hepatocellular Carcinoma +

Juvenile Myelomonocytic Leukemia +

Malignant Peripheral Nerve Sheath Tumor +

Mantle Cell Lymphoma +

Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable +

Peripheral T-Cell Lymphoma +

Prostate Carcinoma +

Refractory Anemia With Excess Blasts +

Refractory Anemia With Excess Blasts-2 +

Renal Cell Carcinoma +

Rhabdoid Tumor +

Schwannoma +

Secondary Acute Myeloid Leukemia +

Therapy-Related Acute Myeloid Leukemia +

Thymic Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.